Met Life Investment Management, LLC Adagio Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

May 10, 2024
SELL
$2.97 - $4.83 $20,148 - $32,766
-6,784 Reduced 17.4%
32,195 $100,000
Q3 2022

Jun 14, 2023
BUY
$2.97 - $4.83 $95,619 - $155,501
32,195 New
32,195 $100,000
Q3 2022

Mar 22, 2023
SELL
$2.97 - $4.83 $20,148 - $32,766
-6,784 Reduced 17.4%
32,195 $100,000
Q3 2022

Nov 14, 2022
BUY
$2.97 - $4.83 $95,619 - $155,501
32,195 New
32,195 $101,000
Q2 2022

Aug 11, 2022
SELL
$2.54 - $4.52 $99,006 - $176,185
-38,979 Closed
0 $0
Q1 2022

May 10, 2024
BUY
$3.81 - $10.77 $148,509 - $419,803
38,979 New
38,979 $177,000
Q1 2022

Jun 20, 2023
BUY
$3.81 - $10.77 $148,509 - $419,803
38,979 New
38,979 $177,000
Q1 2022

Mar 22, 2023
BUY
$3.81 - $10.77 $119,020 - $336,444
31,239 Added 403.6%
38,979 $177,000
Q1 2022

May 12, 2022
BUY
$3.81 - $10.77 $119,020 - $336,444
31,239 Added 403.6%
38,979 $178,000
Q4 2021

Jun 21, 2023
BUY
$6.35 - $47.04 $49,149 - $364,089
7,740 New
7,740 $56,000
Q3 2021

May 17, 2024
BUY
$20.88 - $56.08 $161,611 - $434,059
7,740 New
7,740 $326,000
Q3 2021

Jun 21, 2023
BUY
$20.88 - $56.08 $161,611 - $434,059
7,740 New
7,740 $326,000
Q3 2021

Mar 22, 2023
BUY
$20.88 - $56.08 $161,611 - $434,059
7,740 New
7,740 $326,000
Q3 2021

Nov 15, 2021
BUY
$20.88 - $56.08 $161,611 - $434,059
7,740 New
7,740 $327,000

Others Institutions Holding ADGI

# of Institutions
77
Shares Held
63.9M
Call Options Held
2.3K
Put Options Held
2.1K
View Full List

About Adagio Therapeutics, Inc.

ADGI Quotes by TradingView
  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email